逍遥散 (XYS) 是一种传统中药配方，不仅具有良好的抗肿瘤作用，还可以通过调节神经、微生物群、免疫和氧化应激来减轻痛苦、厌食和生活质量 (QoL)。本研究旨在评估 XYS 对接受辅助化疗的乳腺癌患者的生活质量、心理压力和精神健康的影响。这项前瞻性队列研究纳入了 176 名术后接受辅助化疗联合（n = 81）或没有 (n = 95) XYS 进行比较。生活质量问卷 Core-30 (QLQ-C30)、加州大学洛杉矶分校医院焦虑和抑郁量表 (HADS) (UCLA-LS) 以及慢性病治疗精神健康功能评估 (FACIT) -Sp）评分在辅助化疗前（T0）和辅助化疗第一个（T1）、第二个（T2）、第三个（T3）和第四个周期（T4）后进行评估。XYS在T2时改善了QLQ-C30评分（ p = 0.043)、T3 (p = 0.021) 和 T4 (p = 0.040) 以及 T4 时的 QLQ-C30 分数 (p = 0.027)；此外，XYS 在 T2 (p = 0.040)、T3 (p = 0.023) 和 T4 (p = 0.027) 时降低了 QLQ-C30 分数。关于痛苦，XYS 降低了 T2 (p = 0.010)、T3 (p = 0.025) 和 T4 (p = 0.019) 时的 HADS 焦虑评分以及 T3 时 HADS 定义的焦虑评分 (p = 0.038)。 XYS 还降低了 T2 (p = 0.016)、T3 (p = 0.018) 和 T4 (p = 0.017) 时的 HADS 抑郁评分以及 T2 (p = 0.047)、T3 (p = 0.012) 时 HADS 定义的抑郁率) 和 T4 (p = 0.013)。此外，XYS 降低了 T2 时的 UCLA-LS (p = 0.023)，但增强了 T2 (p = 0.029) 和 T4 (p = 0.026) 时的 FACIT-Sp。此外，通过倾向评分匹配进行调整后，大多数重要发现仍然存在。辅助化疗中添加 XYS 改善了乳腺癌患者的生活质量、心理健康和精神健康。版权所有 © 2024 Wang 和 Yin。

Xiaoyaosan (XYS), a traditional Chinese formula, not only has good antitumor effects but also attenuates distress, anorexia, and quality of life (QoL) by regulating neurology, the microbiota, immunology, and oxidative stress. This study aimed to assess the effect of XYS on QoL, psychological pressure, and spiritual well-being in breast cancer patients undergoing adjuvant chemotherapy.This prospective cohort study enrolled 176 postoperative breast cancer patients who received adjuvant chemotherapy combined with (n = 81) or without (n = 95) XYS for comparison. The Quality-of-Life Questionnaire Core-30 (QLQ-C30), Hospital Anxiety and Depression Scale (HADS), University of California Los Angeles (UCLA-LS), and Functional Assessment of Chronic Illness Therapy-Spiritual Well-being (FACIT-Sp) scores were evaluated before adjuvant chemotherapy (T0) and after the first (T1), second (T2), third (T3), and fourth cycles (T4) of adjuvant chemotherapy.XYS improved the QLQ-C30 score at T2 (p = 0.043), T3 (p = 0.021), and T4 (p = 0.040) and the QLQ-C30 score at T4 (p = 0.027); moreover, XYS attenuated the QLQ-C30 score at T2 (p = 0.040), T3 (p = 0.023), and T4 (p = 0.027). Regarding distress, XYS reduced the HADS-anxiety score at T2 (p = 0.010), T3 (p = 0.025), and T4 (p = 0.019) and the HADS-defined anxiety score at T3 (p = 0.038). XYS also decreased the HADS-depression score at T2 (p = 0.016), T3 (p = 0.018), and T4 (p = 0.017) and the HADS-defined depression rate at T2 (p = 0.047), T3 (p = 0.012), and T4 (p = 0.013). In addition, XYS decreased the UCLA-LS at T2 (p = 0.023) but enhanced the FACIT-Sp at T2 (p = 0.029) and T4 (p = 0.026). Furthermore, after adjustment via propensity score matching, most of the significant findings remained.The addition of XYS to adjuvant chemotherapy improved QoL, psychological health, and spiritual well-being in breast cancer patients.Copyright © 2024 Wang and Yin.